drugset
drugset / Trial / NCT04938635

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

NCT04938635 ↗

Phase 2 Withdrawn Vifor (International) Inc. Labcorp Corporation of America Holdings, Inc · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.

Timeline

Start
2021-09-20
Primary completion
2023-07
Completion
2023-07

Outcome

Outcome not reported

Stopped (Business): “Strategic reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Vamifeport Small molecule 60 mg Oral
Subject Vamifeport Small molecule 120 mg Oral

Indications

beta thalassemia